Spelling suggestions: "subject:"botulinum toxic."" "subject:"botullinum toxic.""
61 |
Estudo comparativo entre a administração de toxina botulínica "A" e a orquiectomia no tratamento da hiperplasia prostática benigna do cão /Mostachio, Giuliano Queiroz. January 2008 (has links)
Orientador: Wilter Ricardo Russiano Vicente / Banca: Maria Denise Lopes / Banca: Maria Isabel de Mello Martins / Resumo: A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, sendo que 80% dos cães com cinco anos apresentam evidências histológicas de sua presença. A fisiopatologia da doença não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado na próstata, mostrando que esta induz atrofia do parênquima e redução do volume. Como o cão é o único animal doméstico que apresenta esta alteração, este se apresenta como modelo experimental para novos estudos da HPB humana. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da TB-A sobre a próstata, libido e qualidade do sêmen, comparando os dados com animais orquiectomizados. Para tanto, 18 cães adultos, com evidências ultra-sonográficas de HPB foram submetidos à castração ou administração de 250 ou 500 U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento para a HPB, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações significativas na libido, ereção ou qualidade e características seminais. Efeitos locais e sistêmicos também não foram observados. Administração de 250 U da TB-A promoveu redução máxima de 9,4% do volume prostático, entretanto, tal redução não foi significativa. Por outro lado, a administração de 500 U de TB-A reduziu significamente as variáveis comprimento, altura e volume da próstata. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina. / Abstract: Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 - 2 years. 80% of 5 years-old dogs have histologic evidences of BPH. Despite the little knowledge concerning about this disease, dihydrotestosterone is the main involved hormone. Recently, the effect of botulinum toxin A (BT-A) on rat and human prostate was investigated, and prostatic parenchyma atrophy and decrease in glandular volume were observed. The dog is one of a few animals that can develop BPH spontaneously and is frequently used as an animal model for human prostatic hyperplasia. Based on that, this study aimed to provide information on BT-A effects on prostate, libido and semen quality, in comparison to orchiectomized dogs. For that, 18 adults dogs, with Ultrasonographic evidences of BPH were submitted to orchiectomy or administration of 250 or 500 U of BT-A, and evaluated along 16 weeks. Orchiectomy presented excellent results on BPH, reducing the prostate volume up to 80%. Administration of BT-A did not significantly interfered on libido, erection or semen characteristics. Local and systemic effects also were not observed. Administration of 250 U of BT-A has promoved a maximum decrease of 9,4% on prostatic volume. However, this reduction was not statistically significant. On the other hand, 500 U of BTA administration has shown to significantly reduce the length, height and volume of prostate. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate. / Mestre
|
62 |
Estudo comparativo do tratamento da retração da pálpebra superior com toxina botulínica tipo A em pacientes nas fases aguda e crônica da orbitopatia distireoidiana ao longo de 6 meses de seguimento / Comparative study of botulinum toxin type A injection treatment for upper eyelid retraction with six-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stagePatricia Grativol Costa 21 July 2008 (has links)
INTRODUÇÃO: O objetivo do presente estudo é apresentar dados morfométricos da fenda palpebral e da função do músculo levantador da pálpebra superior, ao longo de 6 meses de seguimento, após a aplicação da toxina botulínica tipo A, em pacientes com retração palpebral nas fases aguda e crônica da orbitopatia distireoidiana. MÉTODOS: Estudo prospectivo, no qual foram incluídos 24 indivíduos, divididos em dois grupos, agudos (n=12) e crônicos (n=12). Foram submetidos à aplicação de toxina botulínica na dose de 5 UI/0,1 ml em uma das pálpebras superiores e seguidos por 6 meses. A avaliação palpebral foi registrada por meio de captação de imagens com uma câmera filmadora de vídeo conectada a um microcomputador. Os valores médios obtidos nos diferentes momentos analisados foram comparados entre os dois grupos. RESULTADOS: A maioria dos pacientes apresentou melhora da retração da pálpebra superior, com redução média de 3,05 mm no grupo agudo e 3,81 mm no grupo crônico. Esta redução foi significativa até 1 mês no grupo agudo e até 3 meses no grupo crônico. Houve diminuição da função do músculo levantador e da diferença entre as áreas lateral e medial da fenda palpebral nos olhos tratados em ambos os grupos. No olho contralateral, houve aumento significativo da fenda palpebral até 2 semanas após a aplicação. Não houve diferença na freqüência dos efeitos colaterais entre os 2 grupos. CONCLUSÕES: A injeção de 5 unidades foi eficaz na redução da retração e da função do músculo levantador e na melhora do contorno palpebral superior, nos pacientes na fase aguda e crônica da orbitopatia distireoidiana, embora esta melhora tenha sido menos duradoura no grupo agudo / INTRODUCTION: The objective of this study is to compare morphometric data of the eyelid fissure and the levator muscle function after transcutaneous injection of botulinum toxin type A with six-month follow-up in patients with upper eyelid retraction from acute and chronic dysthyroid orbitopathy. METHODS: This was a prospective study that included 24 individuals with dysthyroid orbitopathy, divided into two groups, acute (n=12) and chronic (n=12). They were given a 5 UI/0,1 ml dose of botulinum toxin in the upper eyelid and examined periodically for 6 months. Clinical eyelid examination was performed and recorded using a video camera connected to a microcomputer. Mean values taken at different follow-up points were compared for the two groups. RESULTS: Most patients experienced marked improvement in upper eyelid retraction, with a mean reduction of 3.05 mm in acute group and 3.81 mm in chronic group. This reduction was significantly smaller during 1 month in acute group and during 3 months in chronic group. Reduction in levator function and in the difference between lateral and medial lid fissure measurements was observed in both groups. Measurements of the contralateral eye increased up to 2 weeks after the application. No difference was observed between the study groups with regard to the observed side effects. CONCLUSIONS: A single 5-unit botulinum toxin injection improved upper eyelid retraction, reduced levator function, and produced an adequate lid contour in patients with acute and chronic dysthyroid orbitopathy. The effect lasts longer in patients with chronic disease than in patients with acute disease.
|
63 |
Ação da toxina botulínica tipo A em glândula submandibular de ratosOLIVEIRA, Jaciel Benedito 28 February 2014 (has links)
Submitted by (lucia.rodrigues@ufrpe.br) on 2016-06-08T13:37:15Z
No. of bitstreams: 1
Jaciel Benedito de Oliveira.pdf: 2001810 bytes, checksum: 849f2538ec8321a9c6a102564bb281e9 (MD5) / Made available in DSpace on 2016-06-08T13:37:15Z (GMT). No. of bitstreams: 1
Jaciel Benedito de Oliveira.pdf: 2001810 bytes, checksum: 849f2538ec8321a9c6a102564bb281e9 (MD5)
Previous issue date: 2014-02-28 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / The aim of this study was to observe the morphometric, histological and histométricos aspects of submandibular glands of rats treated with botulinum toxin type A (BTX-A) and with bovine gelatin. We used 80 submandibular glands of adult Wistar rats and divided into three groups: group I, control (n = 14); group II (n = 34) submitted the intraglandular injection of bovine gelatin (0.25 mg); and group III (n = 32) treated with intraglandular injection of botulinum toxin type A (2.5 U). The groups II and III were divided into 3 subgroups according to the day of analysis of glands (7, 15 and 28 days after treatment), when they were removed, heavy and measures immediately for morphometric analysis. Next, were fixed in paraformaldehyde 4 % and processed conventionally for light microscopy, stained in H.E., P.A.S., alcian blue, Gomori trichrome and picrosirius red. Morphometric differences were not observed between subgroups of group III, however in group II there was a significant difference between the three subgroups in the longitudinal length (p = 0.030) and transverse length (p = 0.025), having the gland has shown greater at day 28th after treatment. Histometrically, serous and mucous acini group III, were presented with a smaller diameter compared with the acinithe subgroups treated with bovine gelatina (group II). The wall thickness of the striated duct Group III was lower than in other. Histologically, there was a greater amount of cytoplasmic vacuolization in group III. addition to the greater spacing between the acini. Thus, we conclude that botulinum toxin type A interferes with the structural organization of the submandibular glands, promoting a reduction in the diameter of serous acini and in wall thickness striated ducts, macroscopically but this difference was not significant. / O objetivo deste trabalho foi observar os aspectos morfométricos, histométricos e histológicos das glândulas submandibulares de ratas tratadas com toxina botulínica tipo A (BTX-A) e com gelatina bovina. Foram utilizadas 80 glândulas submandibulares de ratas Wistar adultas e divididas em três grupos: grupo I controle (n = 14); grupo II (n = 34) submetidas a injeção intraglandular de gelatina bovina (0,25 mg); e grupo III (n = 32) tratadas com injeção intraglandular de toxina botulínica tipo A (2,5 U). Os grupos II e III foram divididos em 3 subgrupos de acordo com o dia de análise das glândulas (7, 15 e 28 dias após o tratamento), quando foram removidas, imediatamente pesadas e medidas para análise morfométrica. A seguir, foram fixadas em paraformaldeído 4% e processadas convencionalmente para microscopia de luz, coradas em H.E, P.A.S., alcian blue, tricrômico de Gomori e picrossirius red. Testes estatísticos dos resultados morfométricos e histométricos obtiveram o nível de significância de 0,05 (5%). Morfometricamente não foram observadas diferenças entre os subgrupos do grupo III, entretanto no grupo II houve diferença significativa entre os três subgrupos no comprimento longitudinal (p = 0,030) e comprimento transversal (p = 0,025), tendo a glândula se apresentado maior no 28º dia após o tratamento. Histometricamente, os ácinos serosos e mucosos do grupo III, apresentaram-se com diâmetro menor quando comparado com o ácinos dos subgrupos tratados com gelatina bovina (grupo II). A espessura da parede do ducto estriado do grupo III foi menor que nos demais. Histologicamente, observou-se a maior quantidade de vacuolizações citoplasmáticas no grupo III, além do maior espaçamento entre os ácinos. Dessa forma, concluímos que a toxina botulínica tipo A interfere na organização estrutural das glândulas submandibulares, promovendo uma diminuição no diâmetro dos ácinos serosos e na espessura da parede dos ductos estriados, mas que macroscopicamente tal diferença não se mostrou significante.
|
64 |
Efeito da terapia miofuncional em pacientes com paralisia facial de longa duração associada à aplicação de toxina botulínica / Effect of the muscular-function therapy in patients with long-standing facial paralysis associate to the botulinum toxin applicationPaula Nunes Toledo 06 February 2007 (has links)
INTRODUÇÃO: A paralisia facial é constrangedora tanto do ponto de vista funcional quanto estético. Esta pesquisa teve por objetivo verificar o efeito da terapia miofuncional em pacientes com paralisia facial de longa duração associada à aplicação de toxina botulínica. MÉTODOS: Foram tratados vinte e cinco pacientes, divididos em dois grupos. Os pacientes do grupo A receberam quatro sessões de terapia miofuncional antes da aplicação de toxina botulínica e os pacientes do grupo B simultaneamente à aplicação. A terapia foi composta por manobras isométricas e isotônicas passivas, intra e extraorais, além de exercícios de resistência. RESULTADOS: Após a terapia miofuncional os pacientes apresentaram aumento significativo da mobilidade do lado paralisado da face, do índice de satisfação do paciente com a face, do Índice Funcional da Face (IFF) e do Índice de Bem-Estar Social (IBES). O grupo de pacientes que realizaram a terapia miofuncional previamente, apresentou freqüência significativamente maior de dificuldade para falar, enquanto o grupo que realizou a terapia miofuncional a partir da data da aplicação de toxina botulínica, apresentou freqüência significativamente maior de dificuldade para mastigar. A terapia miofuncional promove simetria facial; satisfação dos pacientes com a face, funcionalidade oromiofacial, qualidade de vida e deve ser realizada antes e após aplicação de toxina botulínica para reduzir os possíveis efeitos adversos. / INTRODUCTION: The facial paralysis is constraining so much of the functional point of view as aesthetic. This research had for goal verified the myofunctional therapy effect in patients with long-standing facial paralysis associate to the botulinum toxin application. METHODS: Twenty-five patients were treated, divided into two groups. The patients from the group A received four sessions of myofunctional therapy before the toxin botulinum application and the patients from the group B received it simultaneously to the application. The therapy was composed by isometric and passive isotonic maneuvers, inside and outside oral, and resistance exercises. RESULTS: After the myofuncional therapy the patients presented significant increase of the mobility of the paralyzed side, of the patient satisfaction index with the face, Functional Index of the Face (IFF) and of the Index of Social Welfare (IBES). The group of patient that accomplished the myofuncional therapy previously presented significantly larger frequency of talking difficulty, while the group that accomplished the miofuncional therapy from the toxin botulínica application date presented significantly larger frequency of chewing difficulty. The myofuncional therapy promotes facial symmetry; patients satisfaction with the face, myofuncional functionality, life quality, and should be accomplished before and after toxin botulínica application to reduce the possible adverse effects.
|
65 |
Ergoterapie u pacientů po aplikaci botulotoxinu. Podtitul: Ovlivňování funkční nezávislosti u dospělých pacientů po získaném poškození mozku / Occupational therapy for patients after the application botulinum toxin. Subtitle: Influencing of functional independence in adult patients after acquired brain injurySobelová, Veronika January 2017 (has links)
This Master's thesis focuses on Occupational therapy for patients after application of botulinum toxin to upper limb. The aim of the thesis was to evaluate and compare a progress of functional independence in patients after acquired brain injury. There were twenty patients involved in the research, who were further divided into two groups and separated by ten people in each group. Both groups underwent the application of botulinum toxin whereas the experimental group A went through the occupational therapy. The control group had ordinary rehabilitation at home and without any occupational intervention for the duration of twelve week under guided self-rehabilitation contract of spastic paresis, so-called GSC. A programme of the group A included over the counter rehabilitation outpatient occupational therapy. The patients attended the course twice a week for the duration of four weeks. Afterwards, they received a home programme for the duration of eight weeks, during which they had two examinations at occupational therapy. All the participants were evaluated by Global Subjective Self-Assessment which is focused on spasticity. There were further evaluated according to Functional Independece Measure and modified Frenchay Arm Test. The experimental group with outpatient occupational therapy was...
|
66 |
TOXINA BOTULÍNICA TIPO A COMO ADJUVANTE NO CONTROLE DA DOR PÓS-OPERATÓRIA EM CADELAS SUBMETIDAS À MASTECTOMIA / BOTULINUM TOXIN TYPE A AS AN ADJUNCT IN THE CONTROL OF POSTOPERATIVE PAIN IN DOGS UNDERGOING MASTECTOMYVilhegas, Sérgio 23 September 2013 (has links)
Made available in DSpace on 2016-01-26T18:55:37Z (GMT). No. of bitstreams: 1
Sergio Vilhegas.pdf: 700648 bytes, checksum: 61199638be80e4484e7e0b1e44be0387 (MD5)
Previous issue date: 2013-09-23 / The aim of this study was to evaluate the analgesic effects of botulinum toxin as an adjunct in the control of postoperative pain in dogs. In a blinded study, sixteen dogs undergoing mastectomy were randomly assigned to two groups of 08 animals each and received 7U kg-1 of botulinum toxin diluted in 10mL of saline and administered 1mL in each breast, subcutaneously (TXB) or 1mL of saline administered in each breast (Control), subcutaneously. After twenty four hours, pre-anesthetic medication was intramuscular (IM) acepromazine (0.03mg kg-1) in combination with morphine (0.3mg kg-1). Anesthesia was induced with intravenously (IV) propofol (4 to 5mg kg-1) and maintained with isoflurane. The analgesic intra-operative support was provided by IV continuous rate morphine (0.1mg kg-1h-1). Heart rate, respiratory rate, systolic arterial blood pressure, oxicapnografy and end-tidal concentration of isoflurane were evaluated during the surgery. Postoperative analgesia was assessed during the first 72 hours after the tracheal extubation using a Visual Analog Scale (VAS) and Glasgow Modified Scale (GMS). Rescue analgesia with morphine (0.5mg kg-1 IM) was performed if the evaluation score exceeded 50% of VAS and/or 30% of GMS during the postoperative period. The pain scores were lower in TXB group than in Control group from 8 to 60 hours and from 12 to 60 hours post-extubation, according to VAS and GMS scales, respectively. Postoperative rescue analgesia was lower in the TXB group (2 of 8 dogs), when compared with Control group (7 of 8 dogs). Cardiopulmonary established was detected in both treatment groups. Preemptive botulinum toxin administration is a satisfactory alternative to post-operative management in dogs undergoing mastectomy. / Este estudo teve como objetivo avaliar a administração da toxina botulínica como adjuvante do controle da dor pós-operatória de cães. Em delineamento cego, dezesseis cadelas, encaminhadas para mastectomia radical foram distribuídas aleatoriamente em dois tratamentos: TXB (n=8) administração de 7U kg-1 de toxina botulínica, diluída em 10 mL de solução salina, sendo administrado 1mL em cada mama, por via subcutânea (SC); Controle (n=8) administração de 10 mL de solução salina (1mL em cada mama, SC). Vinte e quatro horas após, os animais foram encaminhados para cirurgia, sendo tranquilizados com acepromazina (0,03mg kg-1) associada à morfina (0,3mg kg-1), por via intramuscular (IM). Transcorridos vinte minutos, iniciou-se a infusão contínua intravenosa (IV) de morfina (0,1mg kg-1 h-1) que foi mantida durante toda a cirurgia. A indução anestésica foi realizada com propofol (4-5mg kg-1, IV), seguindo-se a manutenção da anestesia com isofluorano. Parâmetros avaliados: frequência cardíaca e respiratória, pressão arterial sistólica, oxicapnografia e concentração final expirada de isofluorano. No pós-operatório o grau de analgesia foi mensurado durante 72 horas após a extubação traqueal, utilizando-se a Escala Analógica Visual (EAV) e Escala de Glasgow Modificada (EGM). Analgesia de resgate foi feita com morfina (0,5mg kg-1 IM) em casos do escore de dor ser superior a 50% da EAV e/ou 33% da EGM. Os escores de dor foram inferiores no tratamento TXB de 8 a 60 horas na EAV e de 12 a 60 horas na EGM. A necessidade de suplementação analgésica foi inferior no gruo TXB (2 de 8 animais) em relação ao grupo Controle (7 de 8 animais). Estabilidade cardiorrespiratória foi observada em ambos os tratamentos. A administração preemptiva de toxina botulínica representa uma alternativa viável para o controle da dor pós-mastectomia em cadelas.
|
67 |
TOXINA BOTULÍNICA TIPO A COMO ADJUVANTE NO CONTROLE DA DOR PÓS-OPERATÓRIA EM CADELAS SUBMETIDAS À MASTECTOMIA / BOTULINUM TOXIN TYPE A AS AN ADJUNCT IN THE CONTROL OF POSTOPERATIVE PAIN IN DOGS UNDERGOING MASTECTOMYVilhegas, Sérgio 23 September 2013 (has links)
Made available in DSpace on 2016-07-18T17:53:12Z (GMT). No. of bitstreams: 1
Sergio Vilhegas.pdf: 700648 bytes, checksum: 61199638be80e4484e7e0b1e44be0387 (MD5)
Previous issue date: 2013-09-23 / The aim of this study was to evaluate the analgesic effects of botulinum toxin as an adjunct in the control of postoperative pain in dogs. In a blinded study, sixteen dogs undergoing mastectomy were randomly assigned to two groups of 08 animals each and received 7U kg-1 of botulinum toxin diluted in 10mL of saline and administered 1mL in each breast, subcutaneously (TXB) or 1mL of saline administered in each breast (Control), subcutaneously. After twenty four hours, pre-anesthetic medication was intramuscular (IM) acepromazine (0.03mg kg-1) in combination with morphine (0.3mg kg-1). Anesthesia was induced with intravenously (IV) propofol (4 to 5mg kg-1) and maintained with isoflurane. The analgesic intra-operative support was provided by IV continuous rate morphine (0.1mg kg-1h-1). Heart rate, respiratory rate, systolic arterial blood pressure, oxicapnografy and end-tidal concentration of isoflurane were evaluated during the surgery. Postoperative analgesia was assessed during the first 72 hours after the tracheal extubation using a Visual Analog Scale (VAS) and Glasgow Modified Scale (GMS). Rescue analgesia with morphine (0.5mg kg-1 IM) was performed if the evaluation score exceeded 50% of VAS and/or 30% of GMS during the postoperative period. The pain scores were lower in TXB group than in Control group from 8 to 60 hours and from 12 to 60 hours post-extubation, according to VAS and GMS scales, respectively. Postoperative rescue analgesia was lower in the TXB group (2 of 8 dogs), when compared with Control group (7 of 8 dogs). Cardiopulmonary established was detected in both treatment groups. Preemptive botulinum toxin administration is a satisfactory alternative to post-operative management in dogs undergoing mastectomy. / Este estudo teve como objetivo avaliar a administração da toxina botulínica como adjuvante do controle da dor pós-operatória de cães. Em delineamento cego, dezesseis cadelas, encaminhadas para mastectomia radical foram distribuídas aleatoriamente em dois tratamentos: TXB (n=8) administração de 7U kg-1 de toxina botulínica, diluída em 10 mL de solução salina, sendo administrado 1mL em cada mama, por via subcutânea (SC); Controle (n=8) administração de 10 mL de solução salina (1mL em cada mama, SC). Vinte e quatro horas após, os animais foram encaminhados para cirurgia, sendo tranquilizados com acepromazina (0,03mg kg-1) associada à morfina (0,3mg kg-1), por via intramuscular (IM). Transcorridos vinte minutos, iniciou-se a infusão contínua intravenosa (IV) de morfina (0,1mg kg-1 h-1) que foi mantida durante toda a cirurgia. A indução anestésica foi realizada com propofol (4-5mg kg-1, IV), seguindo-se a manutenção da anestesia com isofluorano. Parâmetros avaliados: frequência cardíaca e respiratória, pressão arterial sistólica, oxicapnografia e concentração final expirada de isofluorano. No pós-operatório o grau de analgesia foi mensurado durante 72 horas após a extubação traqueal, utilizando-se a Escala Analógica Visual (EAV) e Escala de Glasgow Modificada (EGM). Analgesia de resgate foi feita com morfina (0,5mg kg-1 IM) em casos do escore de dor ser superior a 50% da EAV e/ou 33% da EGM. Os escores de dor foram inferiores no tratamento TXB de 8 a 60 horas na EAV e de 12 a 60 horas na EGM. A necessidade de suplementação analgésica foi inferior no gruo TXB (2 de 8 animais) em relação ao grupo Controle (7 de 8 animais). Estabilidade cardiorrespiratória foi observada em ambos os tratamentos. A administração preemptiva de toxina botulínica representa uma alternativa viável para o controle da dor pós-mastectomia em cadelas.
|
68 |
Avaliação do efeito da toxina botulínica no lado são em pacientes com paralisia facial de longa duração / Evaluation of the botulinum toxin effect in the healthy side of patients with long-standing facial paralysisSalles, Alessandra Grassi 22 November 2006 (has links)
INTRODUÇÃO: A paralisia facial de longa duração cursa com déficit funcional e estético, responsáveis por distúrbios psicológicos e prejuízo na qualidade de vida. Mesmo técnicas cirúrgicas modernas de reanimação conseguem restabelecer apenas parcialmente a movimentação emocional e a simetria entre as hemifaces. A toxina botulínica tipo A provoca paralisia muscular flácida reversível, corrigindo desequilíbrios entre músculos agonistas hipoativos e antagonistas relativamente hiperativos. Não há na literatura séries padronizadas com mais de 10 pacientes com paralisia facial tratados por meio da aplicação de toxina botulínica no lado são a fim de obter maior simetria na dinâmica facial na região da boca. MÉTODOS: Este estudo prospectivo teve como objetivo avaliar o efeito do tratamento adjuvante com toxina botulínica no lado são de 25 pacientes com paralisia facial de longa duração, previamente tratados cirurgicamente. O tempo de seguimento foi de 6 meses. Foram métodos de avaliação escala clínica padronizada, grau de satisfação do paciente, Índices de Função Física (IFF) e de Bem-Estar Social (IBES) e eletromiografia de superfície. A dose total de toxina botulínica variou de 15 a 69 U, média 37,9 ± 5,4 U. Dezesseis pacientes apresentaram efeitos adversos com duração média de 14,1 ± 7,3 dias, incluindo dificuldade para articular palavras, beber, mastigar e se adaptar à redução do sorriso. RESULTADOS: 1) Houve redução significante da assimetria entre as hemifaces, de 48,4% após 1 mês e 16,8% aos 6 meses. O ganho de simetria após 1 mês ocorreu em decorrência da diminuição do movimento do lado são, combinada à melhora da avaliação do lado paralisado. Aos 6 meses, com a perda do efeito clínico da toxina botulínica, a nota do lado são voltou a ser semelhante à do pré-tratamento. A redução de assimetria nessa fase ocorreu devido à melhora significante do lado paralisado em relação ao pré-tratamento. 2) A avaliação subjetiva do paciente em relação à simetria apresentou aumento significante, 1 mês e 6 meses em relação ao pré-tratamento. 3) Houve aumento do IFF ao longo do tempo, porém não significante. O IBES apresentou aumento significante aos 6 meses, comparado ao pré-tratamento. 4) Um mês após a aplicação, o efeito da toxina botulínica levou à diminuição significante do potencial de ação do lado não-paralisado. Após 6 meses, o valor voltou a ser semelhante ao do pré-tratamento. CONCLUSÕES: O tratamento proposto permitiu, com técnica minimamente invasiva, obter melhor simetria facial estática, evidenciada pela posição do ângulo da boca, do filtro labial, dos sulcos nasogenianos, do nariz e do supercílio, e melhor simetria dinâmica, principalmente ao sorrir, falar, na exposição dos dentes e na movimentação facial como um todo. Mesmo após a perda do efeito clínico da droga aos 6 meses, houve 18% de melhora da avaliação clínica do lado paralisado em relação ao pré-tratamento, e melhora dos índices de satisfação e qualidade de vida dos pacientes. / INTRODUCTION: Long-standing facial paralysis presents with functional and aesthetic deficits, which are responsible for psychological disturbances and life quality impairment. Even after modern facial reanimation surgical techniques, the emotional movement and the symmetry of the hemifaces is only partially restablished. Botulinum toxin type A causes reversible flacid muscle paralysis, thus correcting imbalances among hypoactive agonists and relatively hyperactive antagonists. There are no standardized series in the literature with more than 10 facial paralysis patients treated with botulinum toxin injection in the non-paralysed side in the mouth area, with the objective of obtaining better dynamic facial symmetry. METHODS: This prospective study had the objective of evaluate, with 6 months follow-up, the effects of the adjuvant treatment using botulinum toxin in the healthy hemiface of 25 patients with long-standing facial paralysis, previously treated surgically. The methods of evaluation were a standardized clinical scale, the patients degree of satisfaction, the Physical Function and Social/well-being Function subscales of the Facial Disability Index and surface electromyography. Total botulinum toxin dose varied from 15 to 69 U, mean 37,9 ± 5,4 U. Sixteen patients presented adverse effects with mean duration time 14,1 ± 7,3 days, including difficulty in speaking, drinking, eating and adapting to the reduced smile. RESULTS: 1) There was significant reduction of facial asymmetry, of 48,4% at 1 month and of 16,8% at 6 months post-treatment. The better symmetry 1 month post-treatment was consequent to reduced movement on the non-paralysed side combined to better evaluation on the paralysed side. At 6 months, the non-paralysed side had similar grading than that of pre-treatment, showing absence of clinical effect of the toxin. At this time, the asymmetry reduction was due to significant increase in the evaluation of the paralysed side in relation to the pre-treatment. 2) Patients satisfaction with facial symmetry showed significant increase, 1 month and 6 months post-treatment. 3) The Physical Function Index increased, but not significantly. The Social/well-being Function Index showed significant increase at 6 months compared to pre-treatment. 4) There was significant decrease in the action potential of the non-paralysed side one month post-injection of the botulinum toxin. After 6 months, the value returned to baseline. CONCLUSIONS: The proposed treatment allowed, with minimally invasive technique, better facial symmetry at rest, evidenced by better mouth, nose and brow position, and on facial movement as a whole, especially when smiling, speaking or exposing teeth. Even after the loss of the clinical effect of the drug at 6 months, there was an 18% increase in the clinical evaluation of the paralysed side in relation to pre-treatment, and increase in the satisfaction and quality of life indexes.
|
69 |
Analyse des facteurs pronostics d’efficacité du traitement de la spasticité par injection de toxine botulinique. De l’analyse du muscle spastique en imagerie ultrasonore à l’immunisation post injection de toxine botulinique / Analysis of prognostic efficacy factors for the treatment of limb spasticity with botulinum toxin injection. From spastic muscle ultrasound analysis to immunization post botulinum toxin injectionsMathevon, Laure 05 June 2018 (has links)
Notre objectif était de rechercher une méthode d’évaluation musculaire afin de déterminer des facteurs de non réponse tissulaire à une injection de toxine botulique (TB) dans un muscle spastique, chez l’adulte post AVC et chez l’enfant paralysé cérébral (PC). Une étude de reproductibilité et 3 revues systématiques de la littérature ont été réalisées. Les mesures échographiques de l’épaisseur et de l’angle des pennation des fibres du muscle gastrocnémien médial en 2D sont reproductibles. La mesure du module d’élasticité par Shear Wave Ultrasound Elastography délivre une information fiable sur la rigidité du muscle gastrocnémien médial spastique au repos.L’analyse du devenir du muscle post-injection rapporte que la TB participe au remodelage du muscle spastique avec une atrophie persistante, répétition d’injections dépendante.L’étude de l’impact des traitements adjuvants à la TB chez l’enfant PC montre que le renforcement musculaire intensif, y compris des muscles injectés, permet de lutter contre l’atrophie sans renforcer la spasticité. Les plâtres d’allongement permettent d’optimiser le fonctionnement articulaire mais les preuves sur la diminution de la raideur musculaire restent faibles. Dans la description des facteurs pronostics d’efficacité, plus de la moitié des patients identifiés comme secondairement non-répondeurs à la TB dans la spasticité des membres ne sont pas immunisés contre la TB. Les anticorps neutralisants ne sont donc pas la principale cause de non-réponse secondaire. Une évaluation de la qualité musculaire échographique comme facteur pronostic de réponse à la TB et pour mesurer l’impact des traitements adjuvants devrait être réalisée régulièrement afin de déterminer à quel moment ces traitements ne sont plus favorables au système musculaire. / The aim was to investigate a muscle evaluation method to determine tissue factors leading to non-responsiveness to an injection of botulinum toxin (BTX) into a spastic muscle in adult post stroke and children with cerebral palsy (CP). A reproducibility study and 3 systematic literature reviews were carried out. 2D ultrasound measurements of thickness and pennation angle of medialis gastrocnemius muscle fibers are reproducible. Measurement of the modulus of elasticity by shear wave ultrasound elastography provides a reliable information about the rigidity of the spastic medial gastrocnemius muscle at rest.Analysis of the post-injection muscle fate found that BTX participates in the remodeling of the spastic muscle with persistent atrophy that is dependent on the repetition of the injections.Analysis of the impact of BTX adjuvant therapies in CP children showed that intensive muscle strengthening, including of the injected muscles, may help combat atrophy without increasing spasticity. Stretching casts are used to optimize joint function, but there is little evidence for a reduction in muscle stiffness. In the description of prognostic efficacy factors, more than half of patients identified as secondariy non-responders to BTX in limb spasticity tests were not immunized against BTX. Neutralizing antibodies were therefore not the main cause for secondary non-responsiveness. An ultrasound evaluation of muscle quality as a prognostic factor for BTX response and to measure the impact of adjuvant treatments must be regularly performed to determine when these treatments are no longer favourable for the muscle system.
|
70 |
Remodelage osseux et pathologies oro-faciales / Bone remodeling and oro-facial pathologiesKün-Darbois, Daniel 13 November 2017 (has links)
Un 1er travail a étudié les effets osseux mandibulaires de l’injection unilatérale dans les muscles masticateurs de toxine botulique (BTX) chez le rat adulte. Ceci entraine une perte osseuse mandibulaire condylienne et alvéolaire homolatérale importante. Une hypertrophie osseuse de l’enthèse d’insertion mandibulaire du muscle digastrique a été observée et pourrait correspondre à une étiologie pour les tori. Les effets de la BTX sur le cartilage articulaire condylien mandibulaire dans le même modèle animal ont été recherchés par analyse microtomographique du cartilage articulaire après augmentation de contraste à l’acétate d’uranyle. Aucune différence d’épaisseur cartilagineuse n’a été mise en évidence entre les groupes contrôles et BTX.Le 3ème travail a consisté en l’étude histologique et microtomographique des tori mandibulaires chez l’homme.Les tori sont différents des exostoses des os longs par plusieurs caractéristiques (dont l’absence de Fe et Al dans la matrice osseuse) et une asymétrie du remodelage osseux a été mise en évidence.La 4ème partie a consisté en l’étude de la qualité osseuse et de la microvascularisation alvéolaire dans un modèle animal d’ostéonécrose mandibulaire (ONM) aux bisphosphonates (BP). Des signes cliniques et microtomographiques d’ONM ont été observés dans la majorité des cas. La minéralisation osseuse était plus élevée après imprégnation en BP. La microvascularisation osseuse alvéolaire apparaissait augmentée après avulsion dentaire chez les animaux contrôles mais pas chez les animaux ayant reçu des BP témoignant ainsi d’un effet anti angiogénique in vivo des BP qui pourrait jouer un rôle dans la physiopathologie de l’ONM. / First, bone changes at the mandible were studied after a unilateral botulinum toxin (BTX) injection in masticatory muscles in adult rats. A major alveolar and condylar bone loss was evidenced. The occurrence of a hypertrophic bone metaplasia at the digastric muscle enthesis was evidenced as well. This could constitute an etiological factor for tori. Then, condylar articular cartilage changes at the mandible were studied in the same BTX animal model, using microtomography after contrast enhancement of cartilage with uranyl acetate. Cartilage thickness measurement showed no difference when comparing control and BTX groups.A third work studied mandibular tori in human using histologic and microtomographic techniques. Tori appeared different from long bone exostoses by several characteristics (absence of Fe and Al in the bone matrix) and a specific asymmetric bone remodeling was evidenced.The fourth part consisted in the study of alveolar mandibular vascularization and quality of the bonematrix in an animal model of osteonecrosis of the jaws(ONJ) after bisphosphonates (BP) injections. Clinical and microtomographic signs of ONJ were found in mostof the cases. An increased mineralization of the alveolar bone was observed after BP impregnation. Microvascularization was increased after tooth extraction in the alveolar bone of control animals but it was impaired in ZA treated rats. Such an in vivo antiangiogenic effect of BPs could play a role in the pathophysiology of ONJ.
|
Page generated in 0.1924 seconds